Share on StockTwits

Illumina (NASDAQ:ILMN) SVP Christian O. Henry sold 20,000 shares of the stock on the open market in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $164.66, for a total value of $3,293,200.00. Following the sale, the senior vice president now directly owns 28,630 shares of the company’s stock, valued at approximately $4,714,216. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Illumina (NASDAQ:ILMN) traded up 0.33% during mid-day trading on Friday, hitting $168.57. The stock had a trading volume of 1,230,066 shares. Illumina has a 52-week low of $72.77 and a 52-week high of $185.00. The stock has a 50-day moving average of $170.4 and a 200-day moving average of $159.8. The company has a market cap of $23.498 billion and a price-to-earnings ratio of 112.23.

Illumina (NASDAQ:ILMN) last released its earnings data on Wednesday, July 23rd. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.07. The company had revenue of $448.00 million for the quarter, compared to the consensus estimate of $426.50 million. During the same quarter in the previous year, the company posted $0.43 earnings per share. The company’s revenue for the quarter was up 29.5% on a year-over-year basis. Analysts expect that Illumina will post $2.29 EPS for the current fiscal year.

A number of analysts have recently weighed in on ILMN shares. Analysts at Stifel Nicolaus initiated coverage on shares of Illumina in a research note on Monday, August 11th. They set a “buy” rating and a $200.00 price target on the stock. Separately, analysts at Goldman Sachs raised their price target on shares of Illumina from $184.00 to $187.00 in a research note on Tuesday, August 5th. Finally, analysts at Tigress Financial initiated coverage on shares of Illumina in a research note on Friday, August 1st. They set a “buy” rating on the stock. Five research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Illumina has a consensus rating of “Buy” and an average price target of $171.81.

Illumina, Inc (NASDAQ:ILMN) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.